Gilead Sciences has said that its antiviral drug, Remdesivir, will be available to patients as early as this week, Gilead Science CEO Daniel O’Day told American television channel CBS.

“We intend to get that to patients in the early part of this next week, beginning to work with the government which will determine which cities are most vulnerable and where the patients are that need this medicine,” O’Day said on CBS’ “Face of the Nation”.